

# SECURITIES & EXCHANGE COMMISSION EDGAR FILING

**Sanara MedTech Inc.**

**Form: 8-K**

**Date Filed: 2020-10-29**

Corporate Issuer CIK: 714256

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2020

**SANARA MEDTECH INC.**  
(Exact name of registrant as specified in its charter)

Texas  
(State or other jurisdiction of incorporation)

000-11808  
(Commission File Number)

59-2219994  
(I.R.S. Employer Identification No.)

1200 Summit Avenue, Suite 414 Fort Worth, Texas  
(Address of principal executive offices)

76102  
(zip code)

Registrant's telephone number, including area code: (817)-529-2300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant Section 12(b) of the Act: None

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
--	--	--

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On October 29, 2020, Sanara MedTech Inc. issued a press release announcing its uplisting to The Nasdaq Capital Market. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section. Further, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended. Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits:**

<u>Exhibit No.</u>	<u>Description</u>
<a href="#">99.1</a>	Press Release issued October 29, 2020 (furnished pursuant to Item 7.01).



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Sanara MedTech Inc.**

Date: October 29, 2020

By: /s/ Michael D. McNeil

\_\_\_\_\_  
Name: Michael D. McNeil

Title: Chief Financial Officer

---

On Thursday, October 29, 2020, at 9:15 AM ET

**Sanara MedTech Inc. Announces Uplisting to The Nasdaq Capital Market**

**FORT WORTH, TX / ACCESSWIRE / October 29, 2020 / Sanara MedTech Inc.** Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara" or the "Company") (OTCQB:SMTI), a provider of wound and skin care products and virtual consult services dedicated to improving patient outcomes, announced today that it has received approval to list its common stock on The Nasdaq Capital Market ("Nasdaq"). Sanara's common stock is expected to begin trading on The Nasdaq Capital Market effective at the opening of trading hours on November 2, 2020 under its current ticker symbol "SMTI."

Sanara's common stock is currently quoted on the OTCQB market, which is operated by the OTC Markets Group Inc.

Ron Nixon, Sanara's Executive Chairman, stated, "Today's announcement is a significant milestone in our efforts to build Sanara into a leading wound and skin medical technology company. We believe that listing on Nasdaq will increase our visibility to the market and expand the investment opportunity to a larger potential investor base. This aligns well with our ultimate goal of increasing long-term shareholder value."

**About Sanara MedTech Inc.**

With a focus on improving patient outcomes through evidence-based healing solutions and services, Sanara MedTech Inc. markets and distributes wound and skin care products, and offers complementary services to physicians, hospitals, clinics, and all post-acute care settings. We are constantly seeking long-term strategic partnerships with a focus on products that produce efficacious outcomes at a lower overall cost. Our products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX<sup>®</sup> Surgical Activated Collagen<sup>®</sup> to the surgical markets as well as the following products to the wound care market: BIAKÖS<sup>™</sup> Antimicrobial Skin and Wound Cleanser, BIAKÖS<sup>™</sup> Antimicrobial Wound Gel, HYCOL<sup>™</sup> Hydrolyzed Collagen, and PULSAR II<sup>™</sup> Advanced Wound Irrigation<sup>™</sup> (AWI). In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy adjunct products, and the oxygen delivery system segment of the healthcare industry. For more information, visit [SanaraMedTech.com](http://SanaraMedTech.com).

**Information about Forward-Looking Statements**

The statements in this press release that do not constitute historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as "may," "will," "would," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among other things, statements regarding the commencement of trading of our common stock on The Nasdaq Capital Market, our goal of increasing long-term shareholder value and expansion of the Company's business in



telehealth and wound care. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the Company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

**Investor Contact:**

Callon Nichols, Director of Investor Relations  
713-826-0524  
[CNichols@sanamedtech.com](mailto:CNichols@sanamedtech.com)

**SOURCE:** Sanara MedTech Inc.